Project Grant R01AI190195
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $775K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- This federal Project Grant award of $1,442,898.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to study the effects of vaccination on outcomes of acute and post-acute respiratory viral infections, including COVID-19, in solid organ transplant recipients. The research aims to better understand the risks of severe respiratory viral infections and associated post-acute syndromes...
- This $3,304,164 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to determine the real-world comparative effectiveness, cost-effectiveness, safety, and impact of the recently approved maternal respiratory syncytial virus (RSV) vaccine and extended-half-life monoclonal antibody products in reducing RSV-associated respiratory morbidities in infants and...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), is supporting a $182,726 research initiative led by Dr. Sara Kim at Seattle Children's Hospital and the University of Washington. The project aims to understand the immune parameters associated with preventing Respiratory Syncytial Virus (RSV) lower respiratory tract infections in hematopoietic cell transplant recipients, a population at high...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), will provide $189,276 to develop an agent-based modeling framework to characterize the burden and prevention strategies for respiratory syncytial virus (RSV) in the United States. The research project aims to establish a detailed understanding of RSV risk and natural history, and produce updated estimates of RSV...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
- This $451,000.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program, supports research to investigate the manipulation of antibody responses by a retrovirus. The research aims to enhance understanding of how pathogens can directly or indirectly modulate B cells, which play a critical role in providing long-term protective immunity. Specifically, the study will examine...
- This $457,778 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a human microphysiological system (MPS) to investigate the peripheral nervous system (PNS) neurotropism of respiratory syncytial virus (RSV) and SARS-CoV-2. The research aims to elucidate the underlying mechanisms contributing to chronic neurological impairments associated with RSV and...
- This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to define the molecular determinants of durable versus non-durable antibody responses in vaccinated individuals. The $777,495 award will fund a 5-year clinical trial to characterize antibody-secreting cell populations and their antibody production over time in response to vaccines that induce...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, awarded a $192,260 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Rector & Visitors of the University of Virginia. The grant will fund research to characterize the systemic and mucosal immune response to adenovirus 40/41 infection in Bangladeshi children and determine the efficacy of breast milk antibodies in providing...
- This federal Project Grant award of $190,944, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to investigate the dynamics and formation of B cell immune memory in human vaccination. The research aims to systematically analyze human B cell, plasma cell, and antibody responses after HIV vaccination, and to dissect the mechanisms by which novel vaccine adjuvants like 3M-052-AF...